With the explosion of GLP-1 medications transforming the weight loss landscape, one question remains unanswered: which GLP-1 is best for weight loss? The answer isn’t as simple as you might think. Some medications offer faster results, while others excel in long-term sustainability—but only one stands out above the rest. Here’s what the data (and doctors) are finally revealing.
TL;DR
GLP-1 medications like semaglutide and liraglutide are effective for weight loss, with semaglutide (Wegovy®) showing greater average results (~15%) compared to liraglutide (~5–6%). Wegovy is FDA-approved for both reduction and cardiovascular risk reduction. Results build gradually, with meaningful reduction often seen by 6 months and peak effects around 15–16 months. Side effects are mostly gastrointestinal and typically mild, but long-term use is crucial to avoid regain.
Get the support you need for weight loss—Contact us to explore GLP-1 treatment options now!
What Are the Most Popular GLP-1 Medications for Weight Loss?
GLP-1 receptor agonists have quickly become the leading class of prescription medications for weight reduction in people with obesity or overweight and related health conditions. Among them, semaglutide (Wegovy®, also sold as Ozempic® and Rybelsus®) is one of the most popular options. Wegovy is FDA-approved for long-term weight management and has shown average loss of 10–15% over about 68 weeks, making it one of the most effective therapies available.
Another commonly used GLP-1 is liraglutide (Saxenda®), approved in late 2020 for weight management at a daily dose of 3.0 mg. It typically results in around 5% loss—less than semaglutide but still clinically meaningful. Other GLP-1s like exenatide and dulaglutide may offer modest benefits but aren’t approved specifically for obesity. Dual-agonists such as tirzepatide, which also target GIP receptors, show even stronger reduction outcomes, though they fall outside traditional GLP-1 monotherapy.
Wegovy for Weight Loss
Wegovy is a prescription medication containing semaglutide, FDA-approved for long-term weight management in adults with a BMI of 30 kg/m² or higher—or 27 kg/m² with related health conditions—as well as adolescents aged 12 and up. It is intended to be used alongside a reduced-calorie diet and increased physical activity.
- Clinical Efficacy
In large-scale clinical trials (the STEP program), Wegovy consistently demonstrated significant loss outcomes. Over a 68-week period, participants taking Wegovy lost an average of approximately 15% of their starting body weight, compared to just 2–3% with a placebo. A majority of users (over 80%) achieved at least 5% loss, and in some trials, around 55% reached a reduction of 15% or more. - Cardio‑metabolic Benefits
As of March 2024, Wegovy is also approved to reduce the risk of major cardiovascular events—such as heart attack and stroke—in overweight or obese adults with established cardiovascular disease. This makes it the first medication to carry this additional indication. - Usage Guidelines
Wegovy is administered as a weekly subcutaneous injection. Treatment begins at a low dose, gradually increasing over approximately 16 weeks to a target dose of 2.4 mg. This slow dose escalation is designed to minimize common gastrointestinal side effects and improve long-term tolerability.
Semaglutide vs. Liraglutide
When comparing semaglutide and liraglutide, clinical trial data reveals clear differences in effectiveness and user experience. In the 68-week STEP 8 randomized trial, semaglutide (2.4 mg weekly) led to an average reduction of 15.8%, significantly outperforming liraglutide (3.0 mg daily), which showed a 6.4% reduction. Participants taking semaglutide were also far more likely to achieve substantial weight loss, with odds of reaching ≥ 10%, ≥ 15%, or ≥ 20% reductions significantly higher—estimated at 6 to 8 times greater than with liraglutide.
Both medications share similar side-effect profiles, most notably gastrointestinal symptoms such as nausea, diarrhea, and constipation. These effects are usually temporary and tend to occur during dose escalation. Nevertheless, semaglutide had a lower discontinuation rate (around 13.5%) compared to liraglutide (approximately 27.6%), suggesting better overall tolerability.
Benefits and Risks of GLP-1
GLP-1 receptor agonists have gained widespread attention for their role in weight management and metabolic health. Originally developed for type 2 diabetes, these medications are now used by a broader population due to their ability to promote meaningful loss and improve related health markers. However, like any medical treatment, GLP-1 therapies come with both benefits and potential risks that should be carefully considered under professional guidance.
Benefits
GLP-1 medications have shown meaningful health benefits. Clinical trials report an average reduction of approximately 10–15% with semaglutide and around 5% with liraglutide, when combined with diet and exercise. Beyond reduction, these treatments are associated with improvements in several metabolic markers, including lower HbA1c, fasting glucose, triglycerides, cholesterol, waist circumference, and blood pressure.
One of the most notable advancements is semaglutide’s FDA-approved indication for reducing major cardiovascular events in overweight or obese adults with established cardiovascular disease.
Risks
While generally well-tolerated, GLP-1 medications are commonly associated with gastrointestinal side effects such as nausea, vomiting, diarrhea, and constipation. These are usually mild to moderate and tend to improve over time. However, rare but serious risks also exist. There is a boxed warning for thyroid C-cell tumors, including medullary thyroid cancer. Though the pancreatitis risk appears low, caution is advised for individuals with a history of the condition. Case reports have raised additional concerns, though causation has not been definitively established.
Regaining after discontinuation is another important consideration. Follow-up data from STEP trial extensions show that many individuals regained about two-thirds of the weight they initially lost within one year of stopping semaglutide, with only about one-third (~5% reduction) maintained after two years.
How Long for Results?
GLP-1 medications produce gradual but meaningful reduction over time, with effects building steadily as treatment progresses. In the first few weeks, appetite suppression typically begins during the early dose-titration phase, although loss at this stage is generally modest. Most patients reach the full maintenance dose by around 16 weeks, setting the stage for more significant outcomes.
By approximately 68 weeks (15–16 months), clinical trials report the most robust results: an average reduction of around 15% with semaglutide and 6% with liraglutide. Nevertheless, meaningful changes are often observed earlier. Achieving ≥ 5% loss by six months is considered clinically significant, and most GLP-1 trials meet or exceed this benchmark. For semaglutide, 10–15% cumulative reduction is typically reached between 9 and 12 months when treatment is consistently followed and combined with diet and exercise.
To maintain results, ongoing use of the medication along with lifestyle support is essential. Discontinuing treatment often leads to regain, with many individuals regaining a substantial portion of the lost. While long-term benefits and safety beyond two years are still being studied, many patients continue to experience gastrointestinal tolerance and sustained metabolic improvements, though individual responses can vary.
Key Takeaways
- GLP-1 Medications for Weight Loss
- GLP-1 receptor agonists are leading treatments for obesity and overweight individuals, with semaglutide and liraglutide being the most widely used.
- Semaglutide (e.g., Wegovy®) is FDA-approved for long-term weight management and has shown 10–15% average loss over 68 weeks.
- Liraglutide (e.g., Saxenda®) provides about 5% average loss and is also FDA-approved, though generally less effective than semaglutide.
- Wegovy’s Clinical Performance
- Wegovy is approved for use in adults and adolescents (12+) with qualifying BMI, in combination with diet and exercise.
- In clinical trials, over 80% of patients achieved ≥5% weight loss; around 55% achieved ≥15%.
- As of March 2024, Wegovy is approved to reduce the risk of cardiovascular events in adults with obesity and heart disease.
- Administered weekly via injection, with gradual dose escalation over 16 weeks to reduce side effects.
- Semaglutide vs. Liraglutide
- Semaglutide outperformed liraglutide in the 68-week STEP 8 trial: 15.8% vs. 6.4% loss on average.
- Odds of achieving ≥10–20% weight loss were 6–8 times higher with semaglutide.
- Both drugs share similar GI side effects, but semaglutide had a lower discontinuation rate (13.5% vs. 27.6%).
- Weekly dosing of semaglutide may offer better convenience and adherence than daily liraglutide.
- Benefits of GLP-1 Medications
- Promote substantial weight loss and improve metabolic health markers (e.g., glucose, cholesterol, blood pressure).
- Semaglutide has an additional approved benefit for reducing cardiovascular risk.
- Some large-scale data suggest potential reductions in neurocognitive and cardiometabolic complications.
- Risks of GLP-1 Medications
- Common side effects include nausea, vomiting, diarrhea, and constipation—typically mild and temporary.
- Serious risks include a boxed warning for thyroid C-cell tumors and a low but noted risk of pancreatitis.
- Weight regain is common after discontinuation; only ~33% of weight loss may be maintained after two years without continued treatment.
- Concerns about misuse or disordered eating patterns highlight the need for medical supervision.
- Timeline for Results
- Appetite suppression begins early; most reach full dose by ~16 weeks.
- Clinically meaningful loss (≥5%) is usually seen by 6 months.
- Peak outcomes (10–15% loss for semaglutide) typically occur between 9–16 months.
- Sustaining results requires ongoing treatment and lifestyle support; stopping often leads to significant regain.
Sources.
Hegland, T. A., Fang, Z., & Bucher, K. (2024). GLP-1 medication use for type 2 diabetes has soared. JAMA, 332(12), 952-953. Retrieved from: https://jamanetwork.com/journals/jama/article-abstract/2823270
Mehrtash, F., Dushay, J., & Manson, J. E. (2025). I Am Taking a GLP-1 Weight-Loss Medication—What Should I Know?. JAMA Internal Medicine. Retrieved from: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2836527